Obese and want to lose weight? Wegovy is not the long-term answer, according to leading weight loss surgeon
Doctor warns that Wegovy may cause weight regain without lifestyle changes. (Representative Image)
A leading New Zealand bariatric surgeon has warned that Wegovy, a newly available weight-loss drug that regulates your appetite and contains semaglutide, is not a standalone solution to obesity and could prove harmful without proper support.
Dr Rowan French, a Waikato-based bariatric surgeon, said the drug, recently made available in New Zealand, may trigger initial weight loss, but long-term results depend heavily on accompanying lifestyle changes.
Also Read: What happens near the Sun? NASA's Parker probe sends closest-ever photos of the Sun, unveils space weather origins'People need to know that it's likely, particularly for someone who's living with severe obesity... their problem is a lifelong one,' Dr French told RNZ. 'While it can be controlled, there's a good chance they will never fully be cured of that.'
Wegovy contains semaglutide, a synthetic version of a gut hormone (GLP-1) that regulates insulin and appetite. While it mimics some effects seen after bariatric surgery, such as reduced hunger, it is delivered via weekly injections into the systemic bloodstream rather than through natural gut pathways. French explained that this difference, combined with the way the body builds tolerance to GLP-1 (a phenomenon called tachyphylaxis), means the drug may lose its effectiveness faster than surgery.
'In other words, as time goes on, the patient will get less and less benefit from the medication,' he said. 'Any suggestion some people should stay on it for life is unlikely to be sensible or beneficial.'
He said that for weight-loss efforts using Wegovy or surgery to succeed, patients must address the psychological and behavioural roots of their eating habits. This includes understanding what triggers overeating and receiving nutritional counselling.'Without external help to understand their drivers to eat and nutritional help to understand the sorts of foods they should be eating — particularly in the first 18–24 months — the medications could prove more harmful than good,' he said.
Also Read: Cheaper than eggs, healthier than meat; the superfood that could save your health and the planet, and we are skipping it The surgeon noted that many patients experience weight regain after initially losing weight on either medication or surgery, especially without proper follow-up. In the case of Wegovy, stopping the drug often results in regained weight. But even staying on it may not guarantee sustained results due to increasing drug tolerance.'We know that, when semaglutide is stopped, in most cases, weight is regained,' he said. 'But we can also predict that if a patient stays on it, they will develop tolerance, because this occurs with bariatric surgery, albeit later in the piece.'
French underscored that obesity should be treated as a chronic disease, often rooted in genetic, early life, and environmental factors. He explained that most people have a genetically determined weight 'set point,' which the body subconsciously defends.'Our primitive brain interprets weight loss from dieting as starvation and starts to fight back,' he said. 'That's why yo-yo dieting often results in regaining more weight than was initially lost.'This process, he added, can raise an individual's set point over time, making long-term weight control increasingly difficult without medical intervention and behavioural support.
Also Read: Men posing as women to get nudes; what's the creepy new catfish trend on OnlyFans?
Another major factor driving obesity, French said, is the rise of ultra-processed foods (UPFs), which he described as 'manufactured to make us eat as much as possible.''These foods make up about 50–60 percent of what we eat now,' he said. 'We know from robust data that they cause metabolic disease, depression, dementia, and even cancer.'He urged patients to focus on eating whole foods 'at least 95 percent of the time,' describing them as items 'your grandma would recognise as food.'French warned that media and celebrity portrayals of Wegovy as a 'miracle drug' may be misleading. While the medication is a powerful tool, he said, it must be part of a comprehensive, multidisciplinary approach involving psychology, nutrition, and exercise.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
43 minutes ago
- Mint
Lawmakers Press FDA to Target Knockoff Weight-Loss Drugs
(Bloomberg) -- Dozens of lawmakers are urging US health regulators to crack down on the booming market for knockoff weight-loss drugs amid mounting concerns over their potential safety risks. On Friday, a group of more than 80 bipartisan lawmakers asked the US Food and Drug Administration to stop counterfeit and copycat versions of GLP-1 drugs like Wegovy and Zepbound from flooding the market — a problem that emerged over the last year. 'We are concerned about recent reports revealing a surge in illegal and counterfeit anti-obesity medications,' they wrote in a letter to FDA Commissioner Marty Makary. 'Undoubtedly, illegal counterfeit medications pose an increased risk to patient safety with sometimes fatal consequences.' The group — spearheaded by Representatives Richard Hudson of North Carolina and Herb Conaway of New Jersey — asked the agency to ramp up enforcement over illegally imported weight-loss drugs. They suggested issuing warning letters and better monitoring non-compliant online retailers and so-called compounding pharmacies that sell the medicines. The lawmakers also said the FDA should work in tandem with US Customs and Border Patrol agents to stop Chinese entities from shipping unsafe weight-loss drugs into the US. They requested an update on the FDA's efforts by July 30, given the 'urgency' of the situation. A spokesperson for the FDA said the agency will work with the US Department of Health and Human Services to provide a 'complete and thorough' response to the issues raised in the lawmakers' letter. 'Any effort to undermine America's supply of safe medicines is an issue that FDA takes seriously,' the spokesperson said. 'And we are deeply committed to strengthening the oversight of imported products at US ports of entry.' In recent years, the popularity of GLP-1 drugs has led to an explosion of copycats and counterfeits made by companies seeking to capitalize on the hype. State-licensed pharmacies were temporarily allowed to make copies of the drugs during a supply shortage, but are no longer permitted to do so after Novo Nordisk A/S and Eli Lilly & Co. boosted production. Still, some pharmacies have refused to wind down their operations while others have pivoted to selling the drugs in lower doses in order to avoid regulatory scrutiny. Counterfeit drugs are made by unregistered entities typically using illegally imported ingredients. As recently as April, there continue to be instances when counterfeit Ozempic pens covertly enter the drug supply chain undetected. Some patients are also purchasing ingredients directly from online sellers in an attempt to make the drugs themselves at home. In both cases, the medications don't go through the same rigorous approval process as brand-name drugs made by Novo and Lilly. Experts worry the lack of oversight is putting patients at risk. The FDA has said it's aware of hospitalizations potentially linked to the copycat drugs, but that adverse events are likely being underreported. 'We support the bi-partisan call for the FDA to crack down on counterfeit and illegally sold weight-loss drugs,' said a spokesperson for Hims & Hers Health Inc., one of the telehealth firms that sells compounded GLP-1s. 'We appreciate lawmakers' recognition that legitimate compounded medications dispensed by state-regulated pharmacies are not counterfeit. Patient safety must always come first.' Novo and Lilly have discouraged consumers from using compounded and counterfeit products, including suing telehealth firms that sell the copycat versions and working with border agents to seize illegal shipments. Under the Biden administration, the companies repeatedly urged the FDA to take action, but the agency mostly limited its actions to issuing consumer warnings — even as its top drug official publicly acknowledged safety concerns. Under the Trump administration, the HHS has also focused more heavily on other issues, such as banning food dyes and examining vaccine schedules. Meanwhile, lawmakers are ramping up their calls for action. State attorneys and other lawmakers have sent letters to the FDA and Federal Trade Commission advocating for greater transparency around the treatments and more scrutiny around marketing practices. (Updates with statement from FDA in sixth and seventh paragraphs.) More stories like this are available on
NDTV
2 hours ago
- NDTV
How Safe Are Your Eyes From Smartphone Light? What Studies Say
Do smartphones affect your eyes? The majority of studies say yes, the smartphone light, particularly blue light, can potentially harm your eyes. Prolonged exposure to blue light has been linked to various issues, including strain in eyes, sleep disruption and retinal damage. Dry eyes, blurred vision and headaches happen because of extended screen time. It also causes suppressed melatonin production, affecting sleep patterns. Such exposure has a potential risk of macular degeneration and cataracts. Notably, the amount of blue light released from smartphone screens is relatively tiny. A 2014 study from Harvard, which talks about the blue-light screen, remains the best evidence for light-emitting devices affecting sleep. The oft-cited study found that sleep gets delayed by an average of 10 minutes due to screen use before bed. However, some experts think it's not much. "The evidence for smartphone use near bedtime affecting sleep and circadian rhythms isn't great," Stuart Peirson, a professor of circadian neuroscience at Oxford University, said as quoted by WIRED. But many experts advise not to use mobile phones before bed, or reduce the screen time overall. According to a vision study by the US-based National Eye Institute, children are more at risk than adults because their eyes absorb more blue light from digital devices. Constant scrolling can distract a person and may stimulate the brain and delay REM sleep. A study revealed that mobile phone addiction is similar to substance addiction when it comes to its impact on brain activity. The study noted that those who were addicted to their phones showed higher levels of anxiety. They also had trouble focusing on tasks when not having their phones. 8 Tips To Protect Your Eyes Screen Settings: Lower brightness, use warmer colour temperatures, and enable night mode. The 20-20-20 Rule: Every 20 minutes, take a 20-second break and focus on something 20 feet away. Blue Light Filters: Enable built-in filters or download apps like Twilight, Flux, or Night Shift. Maintain Proper Distance: Hold your phone at least 16-18 inches away from your eyes. Blink Regularly: Make a conscious effort to blink while using your phone. Wear Blue Light Glasses: Consider glasses that filter out blue light for added protection. Regular Eye Exams: Schedule check-ups to monitor your eye health. Text Size and Glare: Adjust text size and reduce glare to minimise eye strain. Use of Phone in Dark Rooms: Avoid using your phone in dark rooms or with harsh lighting. Take breaks and prioritise eye care practices.
The Hindu
2 hours ago
- The Hindu
ICMR study finds only 28.5% of cancer patients receive radiotherapy in India
Radiotherapy is a cornerstone of cancer treatment in India, yet its expansion is hindered by high investment costs and effective planning, target estimation based on cancer burden are crucial to meet the radiotherapy demands of patients with cancer, noted a recent Indian Council for Medical Research (ICMR) study published in the UK-based BioMed Central (BMC) cancer journal early this month. Major shortfall in radiotherapy access India is faced with a substantial shortfall in radiotherapy utilisation across all cancer types and 28.5 percent of cancer patients receive radiotherapy, which is lower than the estimated optimal rate of 58.4 per cent. Breast, head and neck, lung and cervical cancer account for 60 per cent of India's radiotherapy needs. This underscores the need for interventions to meet the gap in machines required for equitable cancer care,'' said the study. Data from the Australian Collaboration for Cancer Outcomes Research and Evaluation (CCORE) were used by the researchers of ICMR-National Centre for Disease Informatics and Research, Bengaluru, for conducting the study. India accounts for 7 per cent of global cancer incidence, ranking third after China and the USA. By the end of 2025, the incidence of cancer in India is projected to reach 1.57 million cases, posing a significant public health challenge. Cancer burden in India As the fifth leading cause of death in the country, cancer demands urgent attention to improve prevention, diagnosis and treatment. Epidemiological data on stage, subsite and histology from the National Cancer Registry Programme were used to assess the optimal utilisation proportion for India. A sensitivity analysis was carried out. Similarly, the optimal radiotherapy fraction has also been calculated. These measures have been used to estimate the existing radiotherapy utilisation gap by comparing with the current radiotherapy utilisation from the cancer registry as well as to estimate the optimal radiotherapy machines required for the country. This study provides a comprehensive assessment of radiotherapy demand and existing gaps in radiotherapy utilisation and in the number of machines in India based on an epidemiological analysis of the cancer burden from the National Cancer Registry Programme. The study also recommended that India would require 1,585 to 2,545 machines, which may increase to a range of 2,016 to 2,291 external beam radiotherapy machines if the assumptions from previous benchmark studies are followed. This points towards an increasing demand for radiotherapy in the coming years as there is expected to be a 70-100 per cent increase in breast, head and neck and lung cancer in low and middle income countries (LMIC). Among the major indicated cancer sites, the deficit is more prominent in lymphoma and lung cancer (relative deficit of more than 70 per cent), followed by prostate, breast and oesophagus, said the study adding that radiotherapy, plays a crucial role in controlling tumour growth, reducing tumour size pre-surgery, and alleviating pain in advanced stages. Stating that high setup and operational costs are creating a significant gap between demand and resources, the study states that there is a need for greater investment to expand radiotherapy facilities to meet the growing demands of cancer patients. Urgent need to expand machines and reduce inequities The World Health Organization (WHO) recommends a minimum of one radiotherapy machine (external radiotherapy machine) per million population, with an optimal target of four per million, the study stated. For India's projected population of 1.45 billion in 2025, this translates to a need for a minimum of 1,450 machines. Yet, only 794 megavoltage (MV) machines are currently available. The shortfall is about 45 per cent from the minimal required standard, the study said. It further notes that aside from increasing the number of equipment, addressing the inequitable distribution of radiotherapy services is also crucial. To align with the country's cancer burden and ongoing control efforts, India must meet evidence-based targets for radiotherapy machine availability. The country is also ramping up efforts to develop and deploy affordable indigenous radiotherapy machines to improve access and reduce dependence on costly imports,' the study stated. The study notes that there is need for detailed situational study of radiation equipment deployment with its features and complexity, utilisation and throughput is required for informed planning and policymaking. Cancer screening and early detection programmes can facilitate the diagnosis of cancers at earlier stages. This could reduce the required quantum of radiotherapy shortly and thus, improve the overall survival of patients, the study said.
